Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study

Link to article at PubMed

Arch Virol. 2021 Jan 25. doi: 10.1007/s00705-021-04956-9. Online ahead of print.


No specific antiviral drugs have been approved for the treatment of COVID-19. This study aimed to evaluate the efficacy of favipiravir in treatment of COVID-19. This was a multicenter randomized controlled study including 96 patients with COVID- 19 who were randomly assigned into a chloroquine (CQ) group and a favipiravir group. None of the patients in the favipiravir group needed mechanical ventilation (p = 0.129). One patient (2.3%) in the favipiravir group and two patients (4.2%) in the CQ group died (p = 1.00). Favipiravir is a promising drug for COVID-19 that decreases the hospital stay and the need for mechanical ventilation.ClinicalTrials.gov Identifier NCT04351295.

PMID:33492523 | DOI:10.1007/s00705-021-04956-9

Leave a Reply

Your email address will not be published.